GLP-1 Agonists Guide
How GLP-1 receptor agonists work, how they compare, and how to build a protocol that fits your goals
Ask Fox AIPeptide research chat, grounded in peer-reviewed papers.What Are GLP-1 Agonists?
GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mimic a natural gut hormone released after eating. They work through multiple mechanisms: slowing stomach emptying so you feel full longer, reducing appetite signals in the brain, and improving how your body handles blood sugar.
Originally developed for type 2 diabetes, these medications have become the most effective pharmaceutical option for weight loss, with clinical trials showing sustained weight loss of 15-24% of body weight over 12-18 months. The three main compounds differ in which hormone receptors they activate: semaglutide targets GLP-1 only (appetite), tirzepatide adds GIP (direct fat cell engagement), and retatrutide adds glucagon (liver fat mobilization) on top of stronger GIP. Each additional receptor changes not just how much weight you lose, but where it comes from and how your body composition shifts.
GLP-1 Compounds at a Glance
| Compound | Brand Names | Mechanism | Avg. Weight Loss | Status |
|---|---|---|---|---|
| Semaglutide | Ozempic, Wegovy | GLP-1 Receptor Activation | 12–15% | 🟢 FDA Approved |
| Tirzepatide | Mounjaro, Zepbound | Dual GIP/GLP-1 Receptor Activation | 18–21% | 🟢 FDA Approved |
| Retatrutide | Investigational (Phase 2) | Triple Agonist: GLP-1 / GIP / Glucagon | 22–24% | 🟡 Phase 3 Ongoing |
Explore GLP-1 Tools & Guides
Compare Compounds
Side-by-side comparison of semaglutide, tirzepatide, and retatrutide with trial data and dosing protocols.
ExploreDose Frequency & Titration Optimizer
Interactive tool to simulate dose escalation schedules and visualize plasma curves.
CalculateBuild Protocol
Step-by-step wizard to create a personalized GLP-1 protocol with support stack.
StartManaging GLP-1 Fatigue
Why semaglutide, tirzepatide, and retatrutide cause fatigue — and what actually fixes each type.
Read guideSupport Stacks for GLP-1s
How to preserve lean mass during GLP-1 therapy with targeted peptide and nutrition support.
Read guideRetatrutide: Advanced Stack
Dual-axis protocol to protect lean mass while maximizing fat loss on retatrutide.
Read guideExplore All GLP-1 Content
Deep dives, practical protocols, and clinical guidance across all GLP-1 topics.
Browse allFrequently Asked Questions
What are GLP-1 agonists and how do they work?
GLP-1 (glucagon-like peptide-1) agonists mimic a gut hormone that regulates appetite and blood sugar. They slow gastric emptying, reduce hunger signals to the brain, and improve insulin sensitivity. This leads to reduced calorie intake and weight loss of 15-25% of body weight in clinical trials.
What is the difference between semaglutide, tirzepatide, and retatrutide?
Semaglutide (Ozempic/Wegovy) is a pure GLP-1 agonist — it suppresses appetite but cannot directly signal fat cells (GLP-1 receptors aren't expressed in adipose tissue), producing ~15% weight loss and a 60:40 fat-to-lean ratio. Its key advantage is the strongest cardiovascular outcome data (SELECT trial). Tirzepatide (Mounjaro/Zepbound) adds GIP receptor agonism, which directly engages fat cells via thermogenesis — producing 20-22% weight loss and a better 75:25 fat-to-lean ratio in non-diabetic obesity. Retatrutide is a triple agonist with redesigned receptor potencies (2× GIP, 0.5× GLP-1, 0.2× glucagon) — the glucagon component directly mobilizes liver fat (84% reduction in Phase 2), and the stronger GIP was engineered to push through impaired GIP signaling in type 2 diabetes. Phase 3 TRIUMPH-4 showed 28.7% weight loss at 12 mg over 68 weeks; FDA approval anticipated 2027.
Which GLP-1 medication causes the most weight loss?
Retatrutide now leads with 28.7% weight loss at 12 mg over 68 weeks (Phase 3 TRIUMPH-4), followed by tirzepatide at 22.5% over 72 weeks (SURMOUNT-1) and semaglutide at 14.9% over 68 weeks (STEP-1). In the head-to-head SURMOUNT-5 trial, tirzepatide produced 47% more weight loss than semaglutide (20.2% vs 13.7%). Important: TRIUMPH-4 enrolled adults with obesity + knee osteoarthritis; general obesity trials are reading out through 2026. Retatrutide is not yet FDA-approved (anticipated 2027); semaglutide and tirzepatide are.
How long does it take to see results from GLP-1 medications?
Most people notice reduced appetite within the first week. Weight loss typically begins in weeks 2-4. By week 8-12, users commonly see 5-10% weight loss. Maximum effects usually occur at 16-20 weeks on maintenance dose, with continued gradual loss through 68-72 weeks.
What are common side effects of GLP-1 agonists?
The most common side effects are gastrointestinal: nausea (affects 20-40%), vomiting, diarrhea, and constipation. These typically decrease after the first few weeks as the body adjusts. Slow dose escalation reduces side effect severity. Serious but rare risks include pancreatitis and gallbladder issues.
Can I take GLP-1 medications if I have type 2 diabetes?
Yes — GLP-1 agonists were originally developed for type 2 diabetes. Semaglutide (Ozempic) and tirzepatide (Mounjaro) are FDA-approved for diabetes management, improving HbA1c by 1.5-2.3%. However, weight loss results differ between diabetic and non-diabetic populations. In T2D, GIP signaling is impaired (the "incretin defect"), which blunts tirzepatide's body-composition advantage — head-to-head data shows similar fat-to-lean ratios for tirzepatide and semaglutide in diabetic patients. Retatrutide was specifically designed with stronger GIP (2× native) and added glucagon to partially overcome this limitation.
How do I prevent muscle loss while taking GLP-1 medications?
Resistance training 2-4x weekly and high protein intake (1.6-2.2g per kg body weight) are essential. Without exercise, lean mass losses vary by drug: semaglutide shows a 60:40 fat-to-lean ratio (40% of weight lost is lean mass), while tirzepatide achieves 75:25 in non-diabetic populations thanks to GIP receptor activation in fat cells. This body-composition advantage narrows in type 2 diabetes where GIP is impaired. Regardless of drug, training and protein are the biggest levers for preserving muscle.
Medical Disclaimer
The content in this GLP-1 guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.